• Careers
  • Investors
  • News
  • Partnering
  • Contact Us
 
  • Home
  • Our Products
    • Recent Products
    • Consumer Products
    • Medical Devices & Diagnostics
    • Prescription Products
    • Product Coupons
  • Our Caring
    • Our Stories
    • Our Giving
    • Our Responsibility
    • Protecting Our People
    • Company Initiatives
  • Our Company
    • Our Credo Values
    • Our Management Approach
    • Our Citizenship
    • Corporate Governance
    • Company Structure
    • Our People & Diversity
    • Company Publications
    • Our History
  • News
    • All News
    • Corporate News
    • Product And Operating Company News
    • Financial News
    • Media Contacts
    • Product And Operating Company News Archive
  • Text Size
  • Text Only
  • Email to a Friend
  • Printer Friendly
  • RSS

Product and Operating Company News

Need to know more about a new skin care product? A new surgical device? A new pain relief medication? You can search here for the information you need from a Johnson & Johnson company.

< Prev | | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | .... 34 Next >
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes

November 09, 2012

S.M.A.R.T.® Vascular Stent Systems Receive FDA Approval for Use in SFA

November 08, 2012

Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (Tmc435) And Vx-135 For Treatment Of Hepatitis C

November 05, 2012

FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events

November 02, 2012

Johnson & Johnson’s Wellness & Prevention, Inc. and Lake Nona Institute Join Forces to Create Measurable Health and Wellness Community Program

October 23, 2012

SAPPHIRE Worldwide Study Data Presented at TCT 2012 Study demonstrates benefit of Carotid Artery Stenting in Symptomatic and Asymptomatic Patients at High Risk of Surgery

October 23, 2012

< Prev | | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | .... 34 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Employees
  • Careers
  • Investors
  • News
  • Partnering
  • Contact Us
Johnson & Johnson
  • Home
  • Our Products
  • Our Caring
  • Our Company
  • All News
  • Corporate News
  • Product And Operating Company News
  • Financial News
  • Media Contacts
  • Product And Operating Company News Archive
  • Text Size
  • Graphic Version
  • Email to a Friend
  • Printer Friendly
  • RSS

Product and Operating Company News

Need to know more about a new skin care product? A new surgical device? A new pain relief medication? You can search here for the information you need from a Johnson & Johnson company.

This section contains multiple pages. Click on each page number to advance the page.
< Prev | | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | .... 34 Next >
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes

November 09, 2012

S.M.A.R.T.® Vascular Stent Systems Receive FDA Approval for Use in SFA

November 08, 2012

Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (Tmc435) And Vx-135 For Treatment Of Hepatitis C

November 05, 2012

FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events

November 02, 2012

Johnson & Johnson’s Wellness & Prevention, Inc. and Lake Nona Institute Join Forces to Create Measurable Health and Wellness Community Program

October 23, 2012

SAPPHIRE Worldwide Study Data Presented at TCT 2012 Study demonstrates benefit of Carotid Artery Stenting in Symptomatic and Asymptomatic Patients at High Risk of Surgery

October 23, 2012

< Prev | | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | .... 34 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •